Do analysts prefer CPIX or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer RFL or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RFL or TAOX more profitable?

Synaptogenix has a net margin of -2,153.97% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% Synaptogenix -2,153.97% -128.51% -97.54%

Do analysts prefer TAOX or PLYX?

Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 285.26%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Do analysts recommend TAOX or FBIO?

Fortress Biotech has a consensus price target of $17.00, suggesting a potential upside of 527.31%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate PYPD or TAOX?

PolyPid currently has a consensus target price of $11.33, suggesting a potential upside of 115.05%. Given PolyPid's stronger consensus rating and higher possible upside, equities analysts plainly believe PolyPid is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PYPD or TAOX more profitable?

PolyPid has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Synaptogenix -2,153.97% -128.51% -97.54%

Synaptogenix (TAOX) Competitors

$4.05 +0.21 (+5.47%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$4.06 +0.01 (+0.25%)

As of 04:02 AM Eastern

Compare

TAOX vs. CPIX, RFL, PLYX, FBIO, and PYPD

Should you buy Synaptogenix stock or one of its competitors? Synaptogenix's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Rafael (RFL), Polaryx Therapeutics (PLYX), Fortress Biotech (FBIO), and PolyPid (PYPD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Synaptogenix compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cumberland Pharmaceuticals has higher revenue and earnings than Synaptogenix. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.27	-$2.84M	-$0.71	N/A
Synaptogenix	$300K	100.98	-$28.74M	-$3.85	N/A

Cumberland Pharmaceuticals has a net margin of -34.40% compared to Synaptogenix's net margin of -2,153.97%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 0 mentions for Synaptogenix. Cumberland Pharmaceuticals' average media sentiment score of 0.37 beat Synaptogenix's score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Neutral
Synaptogenix	Neutral

Cumberland Pharmaceuticals has a beta of 0.13, suggesting that its share price is 87% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Summary

Cumberland Pharmaceuticals beats Synaptogenix on 10 of the 13 factors compared between the two stocks.

How does Synaptogenix compare to Rafael?

Rafael (NYSE:RFL) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Synaptogenix has a net margin of -2,153.97% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

11.3% of Rafael shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 32.9% of Rafael shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Rafael's average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Company	Overall Sentiment
Rafael	Neutral
Synaptogenix	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synaptogenix has lower revenue, but higher earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	141.30	-$30.52M	-$0.68	N/A
Synaptogenix	$300K	100.98	-$28.74M	-$3.85	N/A

Rafael has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Summary

Rafael beats Synaptogenix on 7 of the 11 factors compared between the two stocks.

How does Synaptogenix compare to Polaryx Therapeutics?

Synaptogenix (NASDAQ:TAOX) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

10.3% of Synaptogenix shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 285.26%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Polaryx Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Polaryx Therapeutics had 3 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Polaryx Therapeutics and 0 mentions for Synaptogenix. Polaryx Therapeutics' average media sentiment score of 0.25 beat Synaptogenix's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Synaptogenix	Neutral
Polaryx Therapeutics	Neutral

Polaryx Therapeutics has lower revenue, but higher earnings than Synaptogenix. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	100.98	-$28.74M	-$3.85	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Summary

Polaryx Therapeutics beats Synaptogenix on 12 of the 15 factors compared between the two stocks.

How does Synaptogenix compare to Fortress Biotech?

Synaptogenix (NASDAQ:TAOX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Fortress Biotech has a consensus price target of $17.00, suggesting a potential upside of 527.31%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Fortress Biotech'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Fortress Biotech	Neutral

Fortress Biotech has a net margin of 163.32% compared to Synaptogenix's net margin of -2,153.97%. Fortress Biotech's return on equity of 83.47% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Fortress Biotech	163.32%	83.47%	42.98%

Fortress Biotech has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	100.98	-$28.74M	-$3.85	N/A
Fortress Biotech	$68.47M	1.32	$6.82M	$2.64	1.03

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Summary

Fortress Biotech beats Synaptogenix on 12 of the 14 factors compared between the two stocks.

How does Synaptogenix compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

PolyPid has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Synaptogenix has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Synaptogenix	$300K	100.98	-$28.74M	-$3.85	N/A

PolyPid currently has a consensus target price of $11.33, suggesting a potential upside of 115.05%. Given PolyPid's stronger consensus rating and higher possible upside, equities analysts plainly believe PolyPid is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PolyPid had 1 more articles in the media than Synaptogenix. MarketBeat recorded 1 mentions for PolyPid and 0 mentions for Synaptogenix. PolyPid's average media sentiment score of 1.83 beat Synaptogenix's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Very Positive
Synaptogenix	Neutral

PolyPid has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

26.5% of PolyPid shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

PolyPid beats Synaptogenix on 9 of the 15 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAOX vs. The Competition

Export

Metric	Synaptogenix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.74M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-1.05	787.27	273.29	25.25
Price / Sales	100.98	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	2.38	12.33	12.92	6.14
Net Income	-$28.74M	$2.82B	$3.47B	$349.01M
7 Day Performance	4.11%	2.60%	0.60%	-0.27%
1 Month Performance	7.71%	6.96%	5.72%	0.68%
1 Year Performance	-30.05%	9.45%	25.33%	14.84%

Synaptogenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
TAOX Synaptogenix	0.1517 of 5 stars	$4.05 +5.5%	N/A	-32.5%	$28.74M	$300K	N/A	4
CPIX Cumberland Pharmaceuticals	0.7262 of 5 stars	$7.71 +0.7%	N/A	+87.0%	$114.31M	$44.52M	N/A	80
RFL Rafael	0.1239 of 5 stars	$2.17 +0.3%	N/A	+67.2%	$111.54M	$980K	N/A	20
PLYX Polaryx Therapeutics	2.8062 of 5 stars	$1.97 -4.9%	$7.67 +289.4%	N/A	$98.16M	N/A	N/A	11
FBIO Fortress Biotech	2.4387 of 5 stars	$2.95 +2.6%	$17.00 +477.2%	-8.1%	$97.62M	$63.26M	1.11	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TAOX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synaptogenix (TAOX) Competitors

TAOX vs. CPIX, RFL, PLYX, FBIO, and PYPD

How does Synaptogenix compare to Cumberland Pharmaceuticals?

Summary

How does Synaptogenix compare to Rafael?

Summary

How does Synaptogenix compare to Polaryx Therapeutics?

Summary

How does Synaptogenix compare to Fortress Biotech?

Summary

How does Synaptogenix compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synaptogenix (TAOX) Competitors

TAOX vs. CPIX, RFL, PLYX, FBIO, and PYPD

How does Synaptogenix compare to Cumberland Pharmaceuticals?

Do institutionals and insiders have more ownership in CPIX or TAOX?

Do analysts prefer CPIX or TAOX?

Which has better earnings and valuation, CPIX or TAOX?

Is CPIX or TAOX more profitable?

Does the media refer more to CPIX or TAOX?

Which has more volatility and risk, CPIX or TAOX?

Summary

How does Synaptogenix compare to Rafael?

Is RFL or TAOX more profitable?

Do institutionals & insiders believe in RFL or TAOX?

Does the media prefer RFL or TAOX?

Do analysts prefer RFL or TAOX?

Which has preferable valuation & earnings, RFL or TAOX?

Which has more volatility & risk, RFL or TAOX?

Summary

How does Synaptogenix compare to Polaryx Therapeutics?

Do institutionals and insiders believe in TAOX or PLYX?

Do analysts prefer TAOX or PLYX?

Is TAOX or PLYX more profitable?

Does the media favor TAOX or PLYX?

Which has stronger earnings and valuation, TAOX or PLYX?

Summary

How does Synaptogenix compare to Fortress Biotech?

Do analysts recommend TAOX or FBIO?

Does the media favor TAOX or FBIO?

Is TAOX or FBIO more profitable?

Which has stronger earnings and valuation, TAOX or FBIO?

Do institutionals and insiders hold more shares of TAOX or FBIO?

Which has more volatility and risk, TAOX or FBIO?

Summary

How does Synaptogenix compare to PolyPid?

Which has more volatility & risk, PYPD or TAOX?

Which has stronger valuation and earnings, PYPD or TAOX?

Do analysts rate PYPD or TAOX?

Does the media prefer PYPD or TAOX?

Is PYPD or TAOX more profitable?

Do institutionals and insiders hold more shares of PYPD or TAOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools